Abstract:Background and purpose:Advanced gastric cancer was incurable.S-1 and docetaxel were effective treatment for the advanced cancer.But toxicities of DCF regimen with standard dose were serious and poor tolerated.This clinical trial evaluated the toxicity and efficacy of first line chemotherapy regimen of low dose docetaxel and S-1 for advanced or recurrent gastric cancer.Methods:Forty eligible patients with advanced or recurrent adenocarcinoma of the stomach were enrolled and treated with intravenous docetaxel 40 mg/m2 on day 1 and oral S-1 80?mg/m2 per day on day 1 to 14 every 3 weeks.Treatment was continued until tumor progression or unacceptable toxicity.Tumor response was evaluated every 3 cycles or tumor progression suspected.Toxicity and clinical benefit response(CBR) of every cycle were recorded.Results:One remnant stomach recurrent cancer patient and 2 peritoneal metastasis patients withdraw in the first cycle because of hemorrhage in upper gastrointestinal and intestinal obstruction.Thirty-seven patients completed at least 1 cycle and received a total of 211 cycles of treatment(median 6,range 3-14).CBR was evaluated in 37 patients: 19(51.3%) effective,17(45.9%) stable and 1(2.7%) patients invalid.All 37 patients were evaluable for efficacy: 1(2.7%) complete response and 15(40.5%) partial responses,17(46.0%) stable disease,4(10.8%) progressive disease.The overall response rate was 43.2% and the tumor control rate was 89.2%.Median progression-free survival and median overall survival times were 6.0 and 11.5 months,respectively.The most common hematologic toxicities were leukopenia/neutropenia(50%),anemia(25%),thrombopenia(2.5%).The most common non-hematologic toxicities were anorexia(50%),appetite loss(47.5%),nausea(30%).Less common toxicities included neurotoxicity(15%),alopecia(12.5%),hand-foot syndrome(7.5%),diarrhea(7.5%),hemorrhage of upper gastrointestinal(5.0%),allergic reaction(2.5%),vomiting(2.5%),abnormal liver function(2.5%).Most toxicities were Ⅰ/Ⅱ grade while few patients had Ⅲ/Ⅳ grade toxicities: 7(17.5%) leukopenia/neutropenia,3(7.5%) appetite loss,4(10.0%)nausea,3(7.5%) anorexia,1(2.5%) thrombopenia,1(2.5%) hemorrhage.2 patients had S-1 20% extenuation due to grade Ⅲ toxicity.Conclusion:lower dose of docetaxel combination with S-1 as a first line treatment for advanced or recurrent gastric cancer is highly effective and well tolerated.

[Complete response in a case of advanced esophageal cancer treated with docetaxel/5-FU/CDDPand S-1/docetaxel as neoadjuvant chemotherapy]

[A case of pathologic complete response of primary esophageal carcinoma treated with 5-FU/CDDP as neoadjuvant chemotherapy]

[A case of advanced esophageal cancer made resectable by preoperative combination therapy with 5-FU and CDDP]

Neoadjuvant docetaxel, oxaliplatin and S‑1 (DOS) combination chemotherapy for patients with resectable adenocarcinoma of esophagogastric junction

A Phase II Study of Neoadjuvant Chemoradiotherapy with Docetaxel, Cisplatin and 5-FU Followed by Surgical Resection in the Treatment of Locally Advanced Esophagogastric Junction Cancer and Locally Advanced Esophageal Cancer

[Curative resection for Stage IV advanced gastric cancer that responded to combination chemotherapy with docetaxel, cisplatin, and S-1]

[A Case of Unresectable Thoracic Esophageal Cancer Responding Well to Multimodal Therapy Including 5-FU plus CDDP plus Pembrolizumab]

A Phase II Study of Early FDG-PET Evaluation after One-Cycle Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy: Final Report.

Anti-PD1/PDL1 Antibodies Plus Chemotherapy As First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma

Complete response of a patient with advanced gastric cancer, showing Epstein-Barr virus infection, to preoperative chemotherapy with S-1 and cisplatin

Phase II Study of Metabolic Response to One-Cycle Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma.

Improved Local Control by Surgery and Paclitaxel-Based Chemoradiation for Esophageal Squamous Cell Carcinoma: Results of a Retrospective Non-Randomized Study.

Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma

[A Case of Pathologically Complete Response after Preoperative Chemotherapy in a Locally Advanced Rectal Cancer]

[Complete Response of Liver Metastases from a HER2-Positive Gastric Cancer Treated with Combined S-1/Trastuzumab Chemotherapy]

Safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (Neo DCF) therapy for locally advanced esophageal cancer: Real world data analysis.

A single centre clinical trial of docetaxel and S-1 combination therapy as first line treatment in patients with advanced or recurrent gastric cancer

Effectiveness of Combination Chemotherapy With Docetaxel, Nedaplatin, and 5-Fluorouracil for Advanced and Recurrent Esophageal Cancer

The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma

[Pathologic Complete Response of Advanced Gastric Cancer after Chemotherapy with S-1 and Oxaliplatin and Conversion Surgery-A Case Report]

First-Line Paclitaxel and Cisplatin in Patients with Advanced Squamous-Cell Carcinoma of the Esophagus